Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill stop the relentless itch of a liver disease? a major trial aims to find out.

NCT ID NCT04950127

Completed Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 3 trial is testing an experimental drug called linerixibat against a placebo in about 238 adults with primary biliary cholangitis (PBC) who suffer from moderate to severe itching. The goal is to see if linerixibat can reduce itch severity and improve quality of life over 24 weeks. Participants take the drug or placebo twice daily and report their itch scores using a 0-to-10 scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called linerixibat
What this could lead to
If it works, this could offer a new treatment option for the debilitating itch that affects many people with primary biliary cholangitis.
What could go wrong
This is an early-stage trial, so the drug may not prove effective or could have side effects. Itching is subjective, making it hard to measure improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholestasis primary biliary cholangitis Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRURITUS

Contacts and locations

Locations

  • GSK Investigational Site

    Erlangen, 91054, Germany

  • GSK Investigational Site

    Münster, 48149, Germany

  • GSK Investigational Site

    Cambridge, CB2 0QQ, United Kingdom

  • GSK Investigational Site

    Durham, DH1 5TW, United Kingdom

  • GSK Investigational Site

    Newcastle upon Tyne, NE4 6BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.